STOCK TITAN

Teladoc Health (NYSE: TDOC) appoints Mark Anquillare to its board

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Teladoc Health, Inc. increased its Board of Directors to ten members and appointed Mark V. Anquillare as an independent director effective August 3, 2026. He joins both the audit and compensation committees and has been designated an “audit committee financial expert” under SEC and New York Stock Exchange rules.

The company states there are no related-party arrangements or transactions requiring disclosure in connection with his appointment. Anquillare will receive the same indemnification protections and be eligible for the standard compensation programs for Teladoc Health’s non‑employee directors. A press release announcing his appointment was issued on August 3, 2026.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Board size ten directors Number of Teladoc Health directors after the increase effective August 3, 2026
Effective date of appointment August 3, 2026 Date Mark V. Anquillare was appointed to the Board of Directors
Exhibit 99.1 date August 3, 2026 Date of Teladoc Health press release announcing Mark V. Anquillare’s board appointment
Board committees 2 committees Audit committee and compensation committee on which Mark V. Anquillare will serve
audit committee financial expert regulatory
"designated an “audit committee financial expert” under SEC and New York Stock Exchange rules"
A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.
Regulation FD regulatory
"Item 7.01 Regulation FD. On August 3, 2026, the Company issued a press release"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
non-executive Chairman other
"said Kenneth H. Paulus, non-executive Chairman of the Teladoc Health board"
A non-executive chairman leads a company's board of directors but does not run day-to-day operations or hold an executive management role; they focus on overseeing strategy, setting board agendas, and holding executives accountable. For investors, this role matters because a capable, independent chair can strengthen corporate governance, reduce management risk, and influence long-term strategy and leadership choices—like a team captain who watches the game and makes calls without playing on the field.
virtual care medical
"Teladoc Health (NYSE: TDOC), the global leader in virtual care"
Healthcare services delivered remotely using video calls, phone, secure messaging, or connected devices that track symptoms and vital signs — essentially a virtual doctor’s visit or digital check-in instead of an in-person appointment. Investors watch virtual care because it can change how quickly a provider or tech company reaches more customers, cuts or shifts operating costs, and alters reimbursement and competitive dynamics, much like online banking reshaped how people access financial services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What change did Teladoc Health (TDOC) make to its board of directors?

Teladoc Health expanded its board to ten directors and appointed Mark V. Anquillare as a new independent director effective August 3, 2026. He will serve on both the audit committee and the compensation committee, adding financial and governance expertise to the board.

What roles will Mark V. Anquillare hold on Teladoc Health’s (TDOC) board?

Mark V. Anquillare will serve as an independent director on Teladoc Health’s board and sit on the audit and compensation committees. He has also been designated an “audit committee financial expert” under SEC and New York Stock Exchange rules, highlighting his financial oversight experience.

Is Mark V. Anquillare considered independent under NYSE rules for Teladoc Health (TDOC)?

Yes. Teladoc Health’s board determined that Mark V. Anquillare is an independent director under New York Stock Exchange listing standards. He is also classified as an audit committee financial expert, which qualifies him to provide enhanced oversight of the company’s financial reporting and controls.

Will Mark V. Anquillare receive the same compensation as other Teladoc Health (TDOC) non-employee directors?

Yes. Teladoc Health states that Mr. Anquillare will be eligible to participate in the same compensation arrangements and programs established for its non‑employee directors. He will also benefit from the standard director indemnification agreement used since October 2020.

How did Teladoc Health (TDOC) communicate Mark V. Anquillare’s appointment to investors?

Teladoc Health issued a press release dated August 3, 2026 announcing Mark V. Anquillare’s appointment to its board. That release, identified as Exhibit 99.1, provides additional background on his prior roles and explains the committees on which he will serve.
FALSE0001477449155 E 44th StreetSuite 1700New YorkNY1001700014774492026-08-032026-08-030001477449dei:FormerAddressMember2026-08-032026-08-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 3, 2026
___________________________________
Teladoc Health, Inc.
(Exact name of registrant as specified in its charter)
___________________________________

Delaware
(State or other jurisdiction of
incorporation)
001-37477
(Commission File Number)
04-3705970
(I.R.S. Employer Identification No.)
155 E 44th Street Suite 1700
New York, NY 10017
(Address of principal executive offices and zip code)
(203) 635-2002
(Registrant's telephone number, including area code)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, par value $0.001 per share
TDOC
The New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective August 3, 2026, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Mark V. Anquillare as a director of the Company. Mr. Anquillare was additionally appointed to each of the audit committee and the compensation committee of the Board. The Board has determined that Mr. Anquillare is an independent director within the meaning of the New York Stock Exchange listing standards and is an “audit committee financial expert” under Securities and Exchange Commission (the “SEC”) and New York Stock Exchange rules.

There are no arrangements or understandings between Mr. Anquillare and any other person pursuant to which he was selected as a director. There are no transactions involving the Company and Mr. Anquillare that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.

Mr. Anquillare will have the same director indemnification arrangement as do the Company’s other directors appointed since October 2020, the form of agreement for which was filed with the SEC on March 1, 2021 as Exhibit 10.2 to the Company’s Annual Report on Form 10-K. Mr. Anquillare will be eligible to participate in the compensation arrangements and programs that are established for the Company’s non-employee directors, as in effect from time to time, which are described in the Company’s Proxy Statement on Schedule 14A filed with the SEC on April 7, 2026.

Item 7.01    Regulation FD.

On August 3, 2026, the Company issued a press release regarding the matter discussed in Item 5.02 of this Current Report. A copy of the press release is furnished herewith as Exhibit 99.1.

The information furnished under this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.


Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
Description
99.1
Teladoc Health, Inc. press release, dated August 3, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 3, 2026
Teladoc Health, Inc.
By:
/s/ Adam C. Vandervoort
Name:
Adam C. Vandervoort
Title:
Chief Legal Officer and Secretary



Exhibit 99.1
Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors
NEW YORK, August 3, 2026 -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare is the former president and chief operating officer of Verisk Analytics, a strategic data analytics and technology partner to the global insurance industry. He will serve on the board’s Audit & Compensation committees.
“Mark’s leadership across the global insurance and analytics sectors, along with his experience guiding public companies through growth and transformation, makes him an outstanding addition to the Board," said Kenneth H. Paulus, non-executive Chairman of the Teladoc Health board. "His perspective on how data, technology and AI are reshaping complex industries will be invaluable as Teladoc Health evolves."
Mr. Anquillare has more than 30 years of financial and executive leadership experience. He served as Verisk’s chief financial officer beginning in 2007, leading the company through its 2009 initial public offering, and later served as Verisk’s chief operating officer, overseeing the company’s insurance and government-facing business as well as several corporate functions.
Throughout his career, Mr. Anquillare has helped companies drive growth, innovation and operating efficiency. He currently serves on the board of Guidewire Software where he chairs the audit committee and is a member of the business opportunities committee. He also serves on the boards of RegEd and Bamboo Insurance, and he previously served on the board of TruBridge. Mr. Anquillare holds an MBA from Rutgers Business School and a BBA from the University of Notre Dame.
“Teladoc Health is uniquely positioned to help healthcare become more connected, intelligent and accessible. I look forward to working with the Board and management team as the company advances innovation and creates long-term value,” said Anquillare.

About Teladoc Health 
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
Investors:  
Michael Minchak  
IR@teladochealth.com  



Media: 
Lou Serio 
PR@teladochealth.com 



Filing Exhibits & Attachments

5 documents